MTOR and acute lymphoblastic leukemia: Despite the therapeutic potential of mTOR inhibition in these subtypes, that might have relevant clinical implications, it is essential to identify which subsets of B-ALL are more likely to respond, in order to successfully test mTOR inhibitors in future clinical trials.